Top

Published in:

01-02-2020 | Ultrasound | Original Article

Predictive factors of an axillary pathological complete response of node-positive breast cancer to neoadjuvant chemotherapy

Authors: Naoko Iwamoto, Tomoyuki Aruga, Shinichiro Horiguchi, Chiaki Saita, Mai Onishi, Risa Goto, Toshiyuki Ishiba, Yayoi Honda, Hiromi Miyamoto, Katsumasa Kuroi

Published in: Surgery Today | Issue 2/2020

Abstract

Purpose

The present study aimed to identify the predictive factors of an axillary pathological complete response (Ax-pCR) in patients with node-positive breast cancer who underwent neoadjuvant chemotherapy (NAC).

Methods

The present study included 219 patients who underwent NAC followed by curative surgery, including axillary lymph node dissection (ALND), for 221 breast cancers between January 2010 and April 2018. All patients were clinically and/or pathologically confirmed to be node-positive at the initial diagnosis. The predictive factors of Ax-pCR were analyzed using a chi-square test and multivariate logistic regression models.

Results

Ninety-five patients (43%) achieved Ax-pCR after NAC. The odds of achieving Ax-pCR were significantly improved when tumors were high grade (odds ratio [OR] 2.20, 95% confidence interval [CI] 1.00–4.84), estrogen receptor (ER) negative (OR 2.65 95% CI 1.23–5.70), ycN0 on ultrasound (US) imaging (OR 3.89, 95% CI 1.90–7.97), and showed a clinical complete response (CR) at the primary site after NAC (OR 4.22, 95% CI 1.59–11.27).

Conclusions

Ax-pCR was more likely to be achieved in patients who were diagnosed with ER-negative and high-grade breast cancer and those with ycN0 and clinical CR at the primary site after NAC than among others. Among these patients, those with initially cN1/N2 might be good candidates for a deescalated treatment strategy after NAC.

Boughey JC, Suman VJ, Mittendorf EA, Ahrendt GM, Wilke LG, Taback B, et al. Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node-positive breast cancer: the American college of surgeons oncology group (ACOSOG) Z1071 clinical Trial. JAMA. 2013;310:1455–61. https://doi.org/10.1001/jama.2013.278932.CrossRefPubMedPubMedCentral

Kuehn T, Bauerfeind I, Fehm T, Fleige B, Hausschild M, Helms G, et al. Sentinel-lymph-node biopsy in patients with breast cancer before and after neoadjuvant chemotherapy (SENTINA): a prospective, multicentre cohort study. Lancet Oncol. 2013;14:609–18. https://doi.org/10.1016/S1470-2045(13)70166-9.CrossRefPubMed

Caudle AS, Yang WT, Mittendorf EA, Black DM, Hwang R, Hobbs B, et al. Feasibility trial for selective surgical localization of axillary lymph nodes containing metastases in breast cancer patients. JAMA Surg. 2015;150:137–43. https://doi.org/10.1001/jamasurg.2014.1086.CrossRefPubMedPubMedCentral

Shin K, Caudle AS, Kuerer HM, Santiago L, Candelaria RP, Dogan B, et al. Radiologic mapping for targeted axillary dissection: needle biopsy to excision. AJR. 2016;207:372–9. https://doi.org/10.2214/AJR.16.16545.CrossRef

Siso C, de Torres J, Esgueva-Colmenarejo A, Espinosa-Bravo M, Rus N, Cordoba O, et al. Intraoperative ultrasound-guided excision of axillary clip in patients with no de-positive breast cancer treated with neoadjuvant therapy (ILINA trial): a new tool to guide the excision of the clipped node after neoadjuvant treatment. Ann Surg Oncol. 2018;25:784–91. https://doi.org/10.1245/s10434-017-6270-z.CrossRefPubMed

Kim EY, Byon WS, Lee KH, Park YL, Youn IY, Choi SH, et al. Feasibility of preoperative axillary lymph node marking with a clip in breast cancer patients before neoadjuvant chemotherapy: a preliminary study. World J Surg. 2018;42:582–9. https://doi.org/10.1007/s00268-017-4171-8.CrossRefPubMed

Wu S, Wang Y, Zhang N, Li J, Xu X, Shen J, et al. Intraoperative touch imprint cytology in targeted axillary dissection after neoadjuvant chemotherapy for breast cancer patients with initial axillary metastasis. Ann Surg Oncol. 2018;25:3150–7. https://doi.org/10.1245/s10434-018-6548-9.CrossRefPubMed

Galimberti V, Cole BF, Zurrida S, Viale G, Luini A, Veronesi P, et al. Axillary dissection versus no axillary dissection in patients with sentinel-node micrometastases (IBCSG 23–01): a phase 3 randomised controlled trial. Lancet Oncol. 2013;14:297–305. https://doi.org/10.1016/S1470-2045(13)70035-4.CrossRefPubMedPubMedCentral

Kantor O, Sipsy LM, Yao K, James TA. A predictive model for axillary node pathologic complete response after neoadjuvant chemotherapy for breast cancer. Ann Surg Oncol. 2018. https://doi.org/10.1245/s10434-018-6345-5.CrossRefPubMed

10.

Vila J, Mittendorf EA, Farante G, Bassett RL, Veronesi P, Galimberti V, et al. Nomograms for predicting axillary response to neoadjuvant chemotherapy in clinically node-positive patients with breast cancer. Ann Surg Oncol. 2016;23:3501–9. https://doi.org/10.1245/s10434-016-5277-1.CrossRefPubMed

11.

Murphy BL, Hoskin TL, Heins CDN, Habermann EB, Judy C, Boughey JC. Preoperative prediction of node-negative disease after neoadjuvant chemotherapy in patients presenting with node-negative or node-positive breast cancer. Ann Surg Oncol. 2017;24:2518–25. https://doi.org/10.1245/s10434-017-5872-9.CrossRefPubMed

12.

Kim JY, Park HS, Kim S, Ryu J, Park S, Kim SI. Prognostic nomogram for prediction of axillary pathologic complete response after neoadjuvant chemotherapy in cytologically proven node-positive breast cancer. Medicine (Baltimore). 2015;94:e1720. https://doi.org/10.1097/MD.0000000000001720.CrossRefPubMedPubMedCentral

13.

Hennessy BT, Hortobagyi GN, Rouzier R, Kuerer H, Sneige N, Buzdar AU, et al. Outcome after pathologic complete eradication of cytologically proven breast cancer axillary node metastases following primary chemotherapy. J Clin Oncol. 2005;23:9304–11.CrossRef

14.

Peppe A, Wilson R, Pope R, Downey K, Rusby J. The use of ultrasound in the clinical re-staging of the axilla after neoadjuvant chemotherapy (NACT). The Breast. 2017;35:104–8. https://doi.org/10.1016/j.breast.2017.05.015.CrossRefPubMed

15.

Schwentner L, Helms G, Nekljudova V, Ataseven B, Bauerfeind I, Ditsch N, et al. Using ultrasound and palpation for predicting axillary lymph node status following neoadjuvant chemotherapy e results from the multi-center SENTINA trial. The Breast. 2017;31:202–7. https://doi.org/10.1016/j.breast.2016.11.012.CrossRefPubMed

16.

Boughey JC, Ballman KV, Hunt KK, McCall LM, Mittendorf EA, Ahrendt GM, et al. Axillary ultrasound after neoadjuvant chemotherapy and its impact on sentinel lymph node surgery: results from the American college of surgeons oncology group Z1071 trial (Alliance). J Clin Oncol. 2015;33:3386–93. https://doi.org/10.1200/JCO.2014.57.8401.CrossRefPubMedPubMedCentral

17.

Gentile LF, Plitas G, Zabor EC, Stempel M, Morrow M, Barrio AV. Tumor biology predicts pathologic complete response to neoadjuvant chemotherapy in patients presenting with locally advanced breast cancer. Ann Surg Oncol. 2017;24:3896–902. https://doi.org/10.1245/s10434-017-6085-y.CrossRefPubMedPubMedCentral

18.

Boileau JF, Poirier B, Basik M, Holloway CM, Gaboury L, Sideris L, et al. Sentinel node biopsy after neoadjuvant chemotherapy in biopsy-proven node-positive breast cancer: the SN FNAC study. J Clin Oncol. 2015;33:258–64. https://doi.org/10.1200/JCO.2014.55.7827.CrossRefPubMed

19.

Gianni L, Pienkowski T, Im YH, Roman L, Tseng LM, Liu MC, et al. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. Lancet Oncol. 2012;13:25–322. https://doi.org/10.1016/S1470-2045(11)70336-9.CrossRefPubMed

Title: Predictive factors of an axillary pathological complete response of node-positive breast cancer to neoadjuvant chemotherapy
Authors: Naoko Iwamoto
Tomoyuki Aruga
Shinichiro Horiguchi
Chiaki Saita
Mai Onishi
Risa Goto
Toshiyuki Ishiba
Yayoi Honda
Hiromi Miyamoto
Katsumasa Kuroi
Publication date: 01-02-2020
Publisher: Springer Singapore
Keywords: Ultrasound
Breast Cancer
Breast Cancer
Ultrasound
Anthracycline
Cytostatic Therapy
Published in: Surgery Today / Issue 2/2020
Print ISSN: 0941-1291
Electronic ISSN: 1436-2813
DOI: https://doi.org/10.1007/s00595-019-01858-x

At a glance: The STEP trials

Springer Medicine

Predictive factors of an axillary pathological complete response of node-positive breast cancer to neoadjuvant chemotherapy

Abstract

Purpose

Methods

Results

Conclusions

At a glance: The STEP trials

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 2/2020

Spinal cord injury following aortic arch replacement

Pancreaticogastrostomy after pancreaticoduodenectomy without suturing the pancreas

Prognostic significance of platelet × C-reactive protein multiplier in patients with esophageal squamous cell carcinoma

Serum procalcitonin as a predictor of infectious complications after pancreaticoduodenectomy: review of the literature and our experience

Postpneumonectomy bronchopleural fistula: analysis of risk factors and the role of bronchial stump coverage

Postoperative nonalcoholic fatty liver disease is correlated with malnutrition leading to an unpreferable clinical course for pancreatic cancer patients undergoing pancreaticoduodenectomy